SPY323.34-0.16 -0.05%
DIA267.74-0.36 -0.13%
IXIC10,687.34+15.07 0.14%

T2 Biosystems Announces CMS Approval Of New Technology Add-On Payment For The T2Bacteria Panel

Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients LEXINGTON, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of

· 09/04/2020 07:02


Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients

LEXINGTON, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) continued the New Technology Add-on Payment (NTAP) for the Company’s T2Bacteria® Panel for Fiscal Year 2021.

With this extension, U.S. hospitals treating Medicare inpatients with sepsis continue to be eligible for a NTAP of $97.50 for the T2Bacteria Panel. This accounts for an additional 65 percent of the average price of the T2Bacteria Panel, to be paid along with the diagnosis-related group (MS-DRG) reimbursement that hospitals receive under the Medicare Hospital Inpatient Prospective Payment System (IPPS) for cases exceeding the MS-DRG payment.

“We are pleased with CMS’s decision to extend the NTAP for the T2Bacteria Panel as it allows greater access and continued favorable reimbursement to healthcare providers for use of this life-saving technology,” said John Sperzel, President and Chief Executive Officer of T2 Biosystems. “According to the Centers for Disease Control and Prevention, each year at least 1.7 million adults in the United States develop sepsis and nearly 270,000 die as a result. With rapid diagnosis and treatment, which our T2Bacteria helps facilitate, we can help reduce these numbers for patients with bloodstream infections by targeting appropriate antibiotics, and improving patient outcomes.”  

The T2Bacteria Panel became the first in-vitro diagnostic test to ever receive approval for a NTAP in 2019, and is the only FDA-cleared test able to identify sepsis-causing bacterial pathogens directly from whole blood, in 3 to 5 hours, without the need to wait for a positive blood culture. The T2Bacteria Panel runs on the Company’s FDA-cleared T2Dx® Instrument.

In 2019, CMS stated, “The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well